AOP Orphan Pharmaceuticals AG, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia13. 5. 2019
AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)21. 2. 2019
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®17. 12. 2018
"AOP Orphan is the European pioneer in Orphan Diseases unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases."
"AOP Orphan having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."
"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."